Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy
NCT02515669Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2015
- Primary completion
- Feb 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of taldefgrobep alfa in Duchenne muscular dystrophy (DMD), sponsored by Roche. Started Dec 2015; status: terminated.
02
Drugs
taldefgrobep alfa
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02515669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515669.